S ignificant pulmonary regurgitation (PR) is common after surgical or percutaneous treatment of pulmonary stenosis and tetralogy of Fallot (TOF) and leads to significant late morbidity and mortality. 1 Optimal timing of pulmonary valve replacement (PVR) and procedures minimizing surgical trauma are therefore important. 2 The new Shelhigh Injectable Stented Pulmonic Valve NR4000-PA MIS (Shelhigh Inc, Union, NJ) offers the possibility of PVR without cardiopulmonary bypass (CPB). Here we report our early experience with the first clinical use of this new device.
Patients and Methods
Patients. Four Figure 1, A and B) , available in sizes 17 to 29 mm. Through a median sternotomy main pulmonary artery (MPA), bifurcation and right ventricular outflow tract (RVOT) were dissected free and 2 purse-string sutures were placed on the distal RVOT. For preinjection preparation, the chosen valve was gently compressed with the supplied loop restrictor, slid into the barrel of the delivery trocar ( Figure 1, C) , and the introducer tip secured on the barrel (Figure 1, D) . After heparinization (Liquemin, Roche Pharma Inc., Reinach, Switzerland; 70 IU/kg body weight), the delivery trocar was introduced through a small incision across the purse-string sutures and the barrel further advanced through the introducer tip into the MPA ( Figure  2 ). Under digital control, the valve was ejected from the barrel while the delivery trocar system was slowly withdrawn. After deployment, the valve was secured with several transmural sutures placed at the proximal and distal rim of the valve. After assessment of the valve performance, the chest was closed in a routine fashion.
Results
Valve insertion, delivery, and placement were successful and hemodynamic performance was excellent in all patients ( Figure E3 , Table E1 ). Before valve insertion, 1 patient required additional reduction plasty of the severely enlarged MPA (33 mm). Early recovery was uneventful and all patients were discharged home. However, 1 patient required reoperation 2 months later due to valve migration with severe MPA obstruction and recurrent PR. This failure is explained by a dilated and conical-shaped MPA (maximal diameter 35 mm), which had not been reduced at the time of valve insertion, and insufficient transmural valve fixation. Routine echocardiographic follow-up after 4, 9, 12, and 18 (median 12.2, range 4.3-18.2) months showed good results in the remaining 3 patients with low gradients in all and moderate paravalvular PR in 1. RV function has recovered to subnormal values in all but the 1 patient with moderate PR. All patients were in New York Heart Association functional class I at the latest follow-up.
Discussion
Because patients with TOF or isolated congenital pulmonary stenosis usually need several cardiac reinterventions in the long term, minimizing procedural invasiveness and risks is mandatory. To date, surgeons reduce the impact of repetitive surgery by performing most of these procedures on a beating heart under normothermia with very low early mortality and morbidity in recent years. The new Shelhigh Injectable Stented Pulmonic Valve now offers the advantage of avoiding completely CPB use. Compared with the percutaneous approach, 3 it offers several advantages. All implant sizes needed are available and the procedure is not limited by small catheters or access vessel diameters. Furthermore, No-Reacttreated biologic implants resist calcification and degeneration with excellent results 4 in contrast to the percutaneously used conduit. 5 Additionally, concomitant procedures frequently necessary on the RVOT or the pulmonary artery can be performed simultaneously. Preoperatively, RVOT and pulmonary artery morphology has to be studied carefully by transthoracic echocardiography and magnetic resonance imaging to determine prosthetic valve size and decide on additional procedures. Our early experience shows that reduction plasty of an enlarged MPA of Ͼ28 mm and semicircular fixation of the implant are mandatory to ensure a stable position and prevent paravalvular regurgitation. Device handling and valve implantation, however, have proven easy and straightforward. The follow-up will provide the necessary information on mid-to longterm performance of the Shelhigh Injectable Stented Pulmonic Valve. 
